on M1 Kliniken AG (isin : DE000A0STSQ8)
M1 Kliniken AG: HAEMATO AG Considers Sale of Trading Segment
M1 Kliniken AG has announced that its majority-held subsidiary, HAEMATO AG, is evaluating a Conditional Binding Offer (CBO) for the sale of its trading segment. The segment in question is the fully owned HAEMATO PHARM GmbH. Both the Executive Board and Supervisory Board of HAEMATO AG are currently reviewing this proposal carefully.
The potential divestment of the trading segment aligns with M1 Kliniken AG’s strategic objective to concentrate efforts on its burgeoning beauty sector. This move could signify a major shift in focus, allowing the company to enhance growth in this area.
Further information from the company is anticipated as the review process progresses, ensuring stakeholders remain informed about any developments.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all M1 Kliniken AG news